This article is for educational purposes only and is not medical or legal advice. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication. Legal status of compounded products can change; verify current status before enrolling in any program.
The 30-second answer
On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed the FDA's decision to remove semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. In plain English: the era of cheap, mass-produced compounded GLP-1s from bulk outsourcing facilities is over.
Here's the important part most headlines are missing: your personalized, patient-specific compounded prescription — written for you by a real prescriber and filled by a licensed pharmacy — is still legal. That's the 503A pathway, and it survived the ruling untouched.
If you've been on a compounded program, this article walks you through exactly what to do next, including three legitimate, licensed paths forward that we've personally vetted.
What the Fifth Circuit actually ruled
The Fifth Circuit issued two decisions on the same day (cases 25-10600 for tirzepatide and 25-10758 for semaglutide), affirming that the FDA acted lawfully when it declared the GLP-1 shortages resolved and removed the drugs from the shortage list.
The plaintiffs were the Outsourcing Facilities Association and North American Custom Laboratories (which operates FarmaKeio). They lost. The court found the FDA's delisting was "neither arbitrary nor capricious," and any procedural issue was "harmless." The opinions are unpublished and persuasive rather than binding — but they close the last realistic legal path to reverse the delisting, unless the Supreme Court gets involved.
What that means functionally: the shortage-list exception is the legal mechanism that allowed pharmacies and outsourcing facilities to mass-produce copycat versions of Ozempic, Wegovy, Mounjaro, and Zepbound during the shortage years. That exception is gone. Bulk production for general inventory is no longer lawful.
The critical distinction: 503A vs. 503B
This is the part everyone glosses over, and it's the entire game.
| Compounding pathway | What it is | Status after August 27, 2026 |
|---|---|---|
| 503B — outsourcing facilities | Mass-produce compounded meds for clinics and telehealth in volume, without individual prescriptions. Priced low because of scale. | Unlawful for general GLP-1 use. Was legal only while GLP-1s were on the shortage list. |
| 503A — patient-specific pharmacy compounding | State-licensed pharmacy fills an individual prescription for a named patient, based on a documented clinical reason. | Still legal. Untouched by the ruling. |
Examples of qualifying clinical reasons under 503A include:
- A genuine allergy to an inactive ingredient in the brand product
- A dose the approved strengths cannot deliver (in-between titration steps)
- Another documented medical necessity
One important note: wanting a lower price is not, by itself, a qualifying reason. "Personalization" is a legal test now, not a marketing term.
Timeline: what happened, when
| Date | What happened |
|---|---|
| March 2022 | Wegovy added to FDA shortage list |
| August 2022 | Ozempic added |
| December 2022 | Mounjaro added |
| April 2024 | Zepbound added |
| October 2024 | FDA resolves tirzepatide shortage |
| December 2024 | FDA confirms tirzepatide resolution |
| Early 2025 | FDA removes semaglutide from shortage list |
| 60–90 days after each delisting | FDA enforcement runway for compounders |
| August 27, 2026 | Fifth Circuit affirms FDA — the last legal fight ends |
Lilly spent roughly $23 billion expanding manufacturing capacity. Novo Nordisk demonstrated it could supply 5.8 million packages of semaglutide per month. Supply is real now. The shortage rationale is finished.
What this means for you (in plain language)
If you get your GLP-1 from a bulk compounding pharmacy or a "research grade" reseller
That path is closing, and some of it was never safe to begin with. Products sold as "research grade" have never been legal for human use. Bulk-compounded products that rested on the shortage exception are no longer lawful for general use.
The good news: you have three legitimate paths forward — all more predictable and better supported than the sketchy sourcing many people got pushed toward during the shortage years.
If you get your GLP-1 through a licensed telehealth program with patient-specific 503A prescriptions
Nothing changed for you. The 503A pathway is intact. Programs that operate through state-licensed pharmacies (like SHED, which works with Strive Compounding Pharmacy, Promise Pharmacy, and Foothills Professional Pharmacy) still write individual prescriptions and fulfill them through licensed pharmacies. That's exactly the model the court affirmed as legal.
If you're on brand-name Ozempic, Wegovy, Mounjaro, or Zepbound
Nothing changed for you either. This ruling doesn't affect FDA-approved products at all. Supply is solid — that's literally why the shortage ended.
Your three real paths forward
We've built GLPTree around helping you find the right GLP-1 path for your body and your budget. Here are the three legitimate options we recommend today, in order of what fits most people:
Path 1: Branded GLP-1 through licensed telehealth (SkinnyRx — Wegovy or Zepbound)
Best for: anyone who wants the exact same medication their doctor would prescribe, delivered through a legitimate telehealth flow.
SkinnyRx connects you with a licensed prescriber who evaluates you for FDA-approved Wegovy or Zepbound. If you qualify, the prescription is filled through a licensed pharmacy and shipped to your door. This is the cleanest path — same molecule, same manufacturer quality, no legal gray area.
What we like: you're getting the actual FDA-approved product. The prescription flow is transparent. Insurance coverage works when you have it, and cash pricing is competitive.
Path 2: Weight-loss specialty telehealth (SkinnyRx — specialty program)
Best for: people who want a program built specifically around weight loss (not general telehealth), with more coaching and follow-up.
SkinnyRx's specialty program is designed around obesity care specifically. You get the same FDA-approved medications, plus a program structure — regular check-ins, dose titration guidance, side-effect support. If you're new to GLP-1s, or you've stopped and want a supported restart, this is the path built for you.
What we like: real specialty focus. The medication is the same FDA-approved product, but the wrap-around care is stronger than generalist telehealth.
Path 3: Licensed 503A compounded (SHED)
Best for: people who need a lower monthly cost and qualify for patient-specific compounded care through a legitimate 503A pathway.
SHED operates through state-licensed compounding pharmacies (Strive, Promise, Foothills — all named in their terms) using the 503A patient-specific pathway that survived the Fifth Circuit ruling. That means every prescription is written for you individually, with a documented clinical basis, and filled by a licensed pharmacy. Not bulk. Not "research grade." Legally prescribed and legally filled.
Important to know: this is not the shortage-era mass compounding that just ended. This is the patient-specific pathway that has always been legal and remains legal. Prices are typically $199–$299 per month depending on program and dose.
What we like: it's the legitimate budget option. If you qualify for patient-specific compounding, SHED gives you a licensed, prescriber-supervised path at a fraction of brand pricing.
What NOT to do
Don't buy "research grade" or "not for human use" peptides. These have never been legal for human use. Recent enforcement actions — including the Connecticut Attorney General's September 2026 settlement with Made-in-China over bootleg GLP-1s (GLP1Authority news digest) — show these products can contain impurities, bacterial contamination, and inconsistent doses. The Brazilian government seized 76,000+ smuggled semaglutide and tirzepatide products in just the first half of 2026. This is a real risk.
Don't buy from unverified international sellers. Refrigeration matters. Chain of custody matters. Licensed pharmacy oversight matters.
Don't stop your GLP-1 cold turkey. If you're currently on a compounded program that's ending, work with a prescriber to bridge to one of the paths above. Sudden discontinuation can trigger rapid weight regain and, for people with diabetes, unstable blood sugar. See our guide to what happens when you stop GLP-1 cold turkey.
The good news you might have missed
This ruling isn't the disaster some headlines are framing it as. Here's the actually positive angle:
- Supply is solid. The shortage ended because Lilly and Novo built real manufacturing capacity. Brand availability is the best it's been in years.
- Legitimate compounding survives. The 503A pathway — the one that always required a real prescriber, a real patient, and a licensed pharmacy — is intact. Programs built on that model can continue to operate.
- Prices are moving. Medicare's Bridge program now offers Wegovy and Zepbound for $50/month for eligible seniors. California's SB 1089 (CalRx GLP-1 partnership) is nearing final approval. Real-world data shows Zepbound cuts total healthcare costs by roughly 25% in adults over 55 within 12 months (Eli Lilly Investor Relations via GLP1Authority). The economics are getting better, not worse.
- You can pick a path with confidence. Instead of the confusing patchwork of shortage-era compounders — some legitimate, many not — you now have a much cleaner set of options. Every path on this page is legal, licensed, and prescriber-supervised.
Frequently asked questions
Is compounded semaglutide still legal in 2026?
Yes, but only through the 503A patient-specific pathway. A state-licensed pharmacy can fill an individual prescription written for a named patient with a documented clinical reason the FDA-approved product won't work. Bulk 503B compounding based on the shortage exception is no longer lawful.
Can I still get compounded tirzepatide?
Yes, under the same 503A conditions. The ruling ended bulk production for general use, not patient-specific compounding.
What if I'm on a compounded program right now?
Ask your prescriber whether your prescription meets the patient-specific standard. If it does, a licensed 503A pharmacy can continue filling it. If it doesn't, transition to an FDA-approved option (Ozempic, Wegovy, Mounjaro, Zepbound) or to a program (like SHED) that operates through the 503A pathway.
Will insurance cover my brand-name GLP-1?
Many employer plans still don't cover GLP-1s for weight loss — about 14% of employers have dropped or plan to drop coverage in 2027, according to STAT News reporting. Medicare's Bridge program offers $50/month for eligible seniors. Cash pricing through telehealth programs like SkinnyRx is often the most predictable path if coverage is limited. See our full guide to what to do when your employer drops GLP-1 coverage.
Is SHED still legal after this ruling?
Yes. SHED operates through state-licensed compounding pharmacies on the 503A patient-specific pathway, not the 503B bulk pathway the ruling addressed. That's specifically the model that survived.
Bottom line
The Fifth Circuit ruling did exactly one thing: it closed the shortage-era loophole that allowed bulk compounders to mass-produce GLP-1s without individual prescriptions. Everything else — patient-specific compounding, brand-name GLP-1s, licensed telehealth, real prescriber relationships — continues exactly as before.
If you've been on a compounded program that just went dark, you have three good options. Pick the one that fits your budget and your goals. All three are legal, licensed, and safe. That's the actual story here.
Sources
- Fifth Circuit Compounded GLP-1 Ruling Analysis — PeptidesBeat (August 2026)
- Appeals Court Backs FDA and Drugmakers in Fight Over Compounded GLP-1s — Law360 via GLP1Authority (August 28, 2026)
- Connecticut AG Settlement Over Bootleg GLP-1 Sales — ABC News via GLP1Authority (September 3, 2026)
- SHED GLP-1 Review 2026 — 503A Pathway and Pharmacy Partners, AccessNewswire (June 2026)
- Zepbound Real-World Cost Analysis — Diabetes, Obesity and Metabolism via Eli Lilly Investor Relations (August 30, 2026)
- Medicare Bridge Program Uptake — NPR via GLP1Authority (August 26, 2026)
Educational content. Not medical or legal advice. Talk to your prescriber before starting, stopping, or switching any medication. Legal status of compounded products can change; verify current status before enrolling.